Open AccessPredicting the evolution of Kaposi sarcoma, in the highly active antiretroviral therapy era
Author(s) -
Emmanuelle Boffi El Amari,
Laurence ToutousTrellu,
Angèle GayetAgeron,
Michèle Baumann,
Gieri Cathomas,
Ingrid Steffen,
Peter Erb,
Nicolas J. Mueller,
Hansjakob Furrer,
Matthias Cavassini,
Pietro Vernazza,
Hans H. Hirsch,
Enos Bernasconi,
Bernard Hirschel
Publication year - 2008
Publication title -
aids
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.195
H-Index - 216
eISSN - 1473-5571
pISSN - 0269-9370
DOI - 10.1097/qad.0b013e3282fc9c03
Subject(s) - medicine , hazard ratio , sarcoma , proportional hazards model , univariate analysis , survival analysis , chemotherapy , confidence interval , oncology , kaposi's sarcoma , stage (stratigraphy) , multivariate analysis , pathology , biology , paleontology , human herpesvirus
The outcome of Kaposi sarcoma varies. While many patients do well on highly active antiretroviral therapy, others have progressive disease and need chemotherapy. In order to predict which patients are at risk of unfavorable evolution, we established a prognostic score.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom